Abstract:With the paradigm shift in the management of ulcerative colitis, the treatment goal has shifted from symptomatic relief alone to dual relief of symptomatic and endoscopic. In recent years, with the in-depth study of the pathogenesis of inflammatory bowel disease, many non-invasive biomarkers have been identified from genomics, proteomics, microbiomics, transcriptomics, metabolomics, etc. These biomarkers have been applied to the diagnosis, efficacy evaluation and prognosis prediction of ulcerative colitis. This article reviews the biomarkers that have been applied in clinical practice, as well as novel and potential ones.